192 related articles for article (PubMed ID: 9844472)
21. Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).
Dubois V; Arpin C; Dupart V; Scavelli A; Coulange L; André C; Fischer I; Grobost F; Brochet JP; Lagrange I; Dutilh B; Jullin J; Noury P; Larribet G; Quentin C
J Antimicrob Chemother; 2008 Aug; 62(2):316-23. PubMed ID: 18467306
[TBL] [Abstract][Full Text] [Related]
22. [Susceptibility to chemotherapeutics and the occurrence of metallo-beta-lactamases in hospital Pseudomonas aeruginosa strains].
Nowak P; Targosz A; Budak A; Oleksiak D; Geza G; Skałkowska M
Med Dosw Mikrobiol; 2006; 58(3):231-7. PubMed ID: 17340998
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
Gelfand MS; Cleveland KO; Mazumder SA
J Antimicrob Chemother; 2009 Jun; 63(6):1297-9. PubMed ID: 19369268
[No Abstract] [Full Text] [Related]
24. A highly carbapenem-resistant Pseudomonas aeruginosa isolate with a novel blaVIM-4/blaP1b integron overexpresses two efflux pumps and lacks OprD.
Maniati M; Ikonomidis A; Mantzana P; Daponte A; Maniatis AN; Pournaras S
J Antimicrob Chemother; 2007 Jul; 60(1):132-5. PubMed ID: 17483142
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia.
Bretonnière C; Jacqueline C; Caillon J; Guitton C; Desessard C; Le Mabecque V; Miégeville AF; Villers D; Potel G; Boutoille D
J Antimicrob Chemother; 2012 Mar; 67(3):780-1. PubMed ID: 22184470
[No Abstract] [Full Text] [Related]
26. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections.
Rubin J; Walker RD; Blickenstaff K; Bodeis-Jones S; Zhao S
Vet Microbiol; 2008 Sep; 131(1-2):164-72. PubMed ID: 18395369
[TBL] [Abstract][Full Text] [Related]
27. [Chemical structure, anti-bacterial activity and pharmacokinetics of aminoglycosides].
Matsumoto T; Kumazawa J
Nihon Rinsho; 1991 Oct; 49(10):2284-90. PubMed ID: 1749084
[No Abstract] [Full Text] [Related]
28. Treatment of Pseudomonas aeruginosa infection.
Eykyn SJ
Br J Hosp Med; 1984 Feb; 31(2):136-40. PubMed ID: 6421353
[No Abstract] [Full Text] [Related]
29. [Trend of therapy in Pseudomonas aeruginosa infections].
Jannuzzi C; Tassara A
G Mal Infett Parassit; 1971 Nov; 23(11):1051-4. PubMed ID: 5004852
[No Abstract] [Full Text] [Related]
30. [Role of antibiotics in infections due to Pseudomonas aeruginosa].
Výmola F; Jedlicková Z
Cesk Epidemiol Mikrobiol Imunol; 1972 Jul; 21(4):176-81. PubMed ID: 4262242
[No Abstract] [Full Text] [Related]
31. Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore.
Koh TH; Wang GC; Sng LH
J Clin Microbiol; 2004 Nov; 42(11):5378-80. PubMed ID: 15528748
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of resistance of Pseudomonas aeruginosa isolates to select antibiotics].
Sekowska A; Janicka G; Wojda M; Wróblewska J; Manysiak S
Pol Merkur Lekarski; 2005 Aug; 19(110):169-71. PubMed ID: 16245425
[TBL] [Abstract][Full Text] [Related]
33. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa.
Rice LB
Clin Infect Dis; 2006 Sep; 43 Suppl 2():S100-5. PubMed ID: 16894511
[TBL] [Abstract][Full Text] [Related]
34. Quantitative variations in beta-lactam antibiotic released endotoxin from Pseudomonas aeruginosa: in-vivo relevance.
Jackson JJ; Kropp H
Prog Clin Biol Res; 1995; 392():235-51. PubMed ID: 8524928
[No Abstract] [Full Text] [Related]
35. Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa.
Ikonomidis A; Tsakris A; Kantzanou M; Spanakis N; Maniatis AN; Pournaras S
FEMS Microbiol Lett; 2008 Feb; 279(1):36-9. PubMed ID: 18070070
[TBL] [Abstract][Full Text] [Related]
36. Emergence of carbapenem-hydrolysing metallo-beta-lactamase VIM-1 in Pseudomonas aeruginosa isolates in France.
Corvec S; Poirel L; Decousser JW; Allouch PY; Drugeon H; Nordmann P
Clin Microbiol Infect; 2006 Sep; 12(9):941-2. PubMed ID: 16882306
[No Abstract] [Full Text] [Related]
37. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
Mizunaga S; Kamiyama T; Fukuda Y; Takahata M; Mitsuyama J
J Antimicrob Chemother; 2005 Jul; 56(1):91-6. PubMed ID: 15890721
[TBL] [Abstract][Full Text] [Related]
38. Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species.
Gupta V
Expert Opin Investig Drugs; 2008 Feb; 17(2):131-43. PubMed ID: 18230049
[TBL] [Abstract][Full Text] [Related]
39. Novel variant (bla(VIM-11)) of the metallo-{beta}-lactamase bla(VIM) family in a GES-1 extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa clinical isolate in Argentina.
Pasteran F; Faccone D; Petroni A; Rapoport M; Galas M; Vázquez M; Procopio A
Antimicrob Agents Chemother; 2005 Jan; 49(1):474-5. PubMed ID: 15616342
[No Abstract] [Full Text] [Related]
40. A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
Evans JC; Segal H
Antimicrob Agents Chemother; 2007 Oct; 51(10):3776-7. PubMed ID: 17682099
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
